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Abstract - We studied TOP2A amplification (using FISH methods), and TOP2A and BRCA1 protein overexpression (im-
munohistochemistry) in four molecular subtypes of breast cancer. Of 53 patients, 32 showed TOP2A and 38 showed 
BRCA1 overexpression. The highest percentage of TOP2A amplification (47.8%) and deletion (13%) was detected in Lu-
minal B subtypes. Of 11 Luminal B tumors with TOP2A amplification, 9 (81.8%) overexpressed TOP2A. BRCA1 protein 
overexpression showed significant positive correlation with TOP2A protein expression. BRCA1 and TOP2A proteins ex-
hibited similar patterns of expression in Luminal B and triple-negative breast cancer, suggesting the same prognosis in 
those patients. 
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Abbreviations: TOP2A – Topoisomerase II A; BRCA1 – Breast Cancer Type 1 Susceptibility Protein; CEF – cyclophosph-
amide, epirubicin and 5-fluorouracil; ER – estrogen receptor; PR – progesterone receptor. 
INTRODUCTION
According to immunohistochemical identification of 
three biological markers, there are four different sub-
types of breast cancer: Luminal A (ER+ and/or PR+, 
HER2-), Luminal B (ER+ and/or PR+, HER2+), HER-2 
positive (ER- and/or PR-, HER2+) and triple-negative 
breast cancer (ER- and/or PR-, HER2-) (Bertolo et al., 
2008, Marchio et al., 2008). 
Some of the most important biological mark-
ers associated with the prediction and prognosis for 
breast cancer therapy are BRCA1 and TOP2A (Ar-
riola et al., 2008, Miyoshi et al., 2008). The TOP2A 
gene is located on the long arm of chromosome 17 
and plays an important role in DNA replication, 
transcription and recombination (Arriola et al., 
2008). The BRCA1 gene is located on chromosome 
17q12-21. BRCA1 gene mutations are responsible 
for about 40-45% of hereditary breast cancers, while 
in sporadic breast cancer those mutations are rare. 
Expression of BRCA1 protein is frequently reduced 
in sporadic breast cancer, suggesting a very impor-
tant and wider role in mammary carcinogenesis 
(Miyoshi et al., 2008). Previously it was observed 
that the BRCA1 protein has different biological 
functions, including roles in cell cycle progression, 
DNA repair processes, DNA damage (responsive 
cell cycle check points), regulation of specific tran-
scriptional pathways and in apoptosis. Breast cancer 
with BRCA1 gene mutations has a high frequency 
of p53 gene mutations, usually linked to a negative 
estrogen and progesterone receptor status (Miyoshi 
et al., 2008). 
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Recently, it has been suggested that the TOP2A 
gene could play a critical role in response to therapy 
of breast cancer cells (Coon et al., 2002). Doxoru-
bicin, epirubicin and other anthracyclines bind to 
TOP2A, resulting in cell cycle arrest and apoptosis 
(Schindlbeck et al., 2010, Brase et al., 2010). Previous 
findings also suggested that TOP2A gene amplifica-
tion and protein overexpression was found in 70% of 
breast cancer cases (Bhargava et al., 2005). 
Little is known about TOP2A gene amplification 
and protein status and their association with BRCA1 
protein expression in four different molecular sub-
types of sporadic breast cancer. This information 
may be of importance for predicting the effect of 
therapy, as the amplification of TOP2A has been as-
sociated with a dose-dependent sensitivity to anthra-
cycline therapy in breast cancer. In addition, results 
from this study will contribute to completing the 
knowledge about the similar pattern of expression 
of TOP2A and BRCA1 in four different molecular 




The study was performed according to the regula-
tions of the local ethics committee. We included 53 
patients with breast cancer who underwent surgery 
from 2009 through 2010. The tissue samples of the 
breast cancer patients were immunohistochemically 
classified into 4 molecular subtypes: Luminal A (20 
cases, 37.7%), Luminal B (23 cases, 43.4 %), HER-2 
positive (6 cases, 11.4%) and triple-negative (4 cases, 
7.5%). 
Immunohistochemistry
The material was fixed in 10% buffered formalin 
solution and embedded in paraffin. The tissue sec-
tions were cut at a thickness of 5 µm, heated at 56°C 
for 60 min, and then deparaffinized and rehydrated 
through a series of xylenes and alcohols, followed 
by an epitope retrieval step in which the tissue sam-
ples were heated in microwave oven (at 680 W, in 10 
mmol/L citrate buffer pH 6.0, for 21 min). Tissue 
sections were treated with 3% H2O2 solution in PBS 
to block endogenous peroxidase activity. The next 
step was incubation with the specific antibody in a 
humidity chamber for 60 min at room temperature 
(Table 1). Immunostaining was performed using the 
streptavidin biotin technique (LSAB+/ HRP Kit, Per-
oxidase Labeling, K0690, DAKO Cytomation, Den-
mark). The immunoreactivity complex was visual-
ized with DAKO Liquid DAB+ Substrate/Chromogen 
System (Code No. K3468) and counterstained with 
Mayer’s hematoxylin (Merck) and examined under a 
light microscope. For TOP2A, the nuclei of 50 tumor 
cells were counted under a microscope by two inde-
pendent examiners, and the proportion of stained 
cells was recorded. A cut-off value of 15% separated 
the negative (≤15%) and positive cases (>15%). 
Overexpression of the BRCA1 protein was iden-
tified when nuclear staining was found in more than 
25% of tumor cells. 
The results of the HER-2 IHC tests were scored 
using the HercepTest scoring system (0-3+). The tu-
mor samples were immunohistochemically scored as 
3+ (strong complete membrane staining is observed 
in >30% of tumor cells), 2+ (weak to moderate com-
plete membrane staining is observed in >30% of tu-
mor cells), 1+ (weak, incomplete membrane staining 
in >30% of tumor cells) and 0 (no staining) for HER-
2. Determinations of estrogen and progesterone re-
ceptors were based on both the intensity and the pro-
portion of nuclear staining (0 to 8). Negative control 
staining was conducted by omission of the primary 
antibody. Paraffin slides of invasive breast carcinoma 
were used as a positive control.
FISH methods
The TOP2A FISH pharmDx TM Kit (DakoCytoma-
tion, Glostrup, Denmark) was used to investigate 
TOP2A gene copy number. The probe mix consist-
ed of a mixture of Texas Red-labeled DNA cosmid 
clones covering the TOP2A (approximately 230 kb) 
amplicon and fluorescein-labeled peptide nucleic 
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acid (PNA) probes for the chromosome 17 centro-
meric region. After deparaffinization and rehydra-
tion, specimens are heated in pre-treatment solution 
at 950C for 10 min. The next step involved a proteo-
lytic digestion using ready-to-use pepsin for 10 min 
at 37°C. Following the heating and proteolytic pre-
treatment steps, the samples were incubated with 
ready-to-use FISH probe mix based on a combina-
tion of PNA (peptide nucleic acid) and DNA tech-
nology. The denaturation of probe and target DNA 
was performed on a heating block at a temperature of 
820C for 5 min and incubated overnight in a humidi-
fied hybridization chamber at 450C. After removal 
of the coverslips, the slides were washed in stringent 
wash buffer at 650C for 10 min followed by buffer 
washes and dehydration. Fluorescence mounting 
media including DAPI was applied and the speci-
mens coverslipped. 
The results were analyzed using a 100-W fluores-
cence microscope fitted with the Texas Red and fluo-
rescein isothiocyanate (FITC) double filter for locat-
ing the invasive tumor areas at low magnification and 
reading the signals at high magnification with a x/60 
oil-immersion objective. Then the TOP2A/CEN-17 
ratio was calculated. For each specimen, the gene 
copy level was assessed in four areas in 60 non-over-
lapping tumor cell nuclei. Sixty nuclei were assessed 
in each area, the chromosome 17 copy numbers were 
counted for each cell, and the ratio of TOP2A sig-
nals to chromosome 17 signals was calculated. The 
normal mean TOP2A to chromosome 17 ratios was 
defined as less than 1.5; a ratio 1.5-2.0 was inter-
preted as a low level of amplification; greater than 2 
was interpreted as high level of gene amplification. 
Normal cells in the analyzed tissue section served as 
Fig. 1. Immunohistochemical staining of TOP2A and BRCA1 
proteins in the Luminal B breast cancer subtype. Representative 
results of immunohistochemical staining for TOP2A (a, b) and 
BRCA1 (c, d) in nuclei of breast cancer cells of the Luminal B 
molecular subtype. Immunoreactive cells – arrow. 
Fig. 2. High level of TOP2A gene amplification in nucleus of 
infiltrative breast cancer cells Luminal B breast cancer subtype. 
Note high level of TOP2A gene amplification in nucleus of breast 
cancer cells (c). FISH analysis shows more than 10 signals per 
cell, indicating a high level of TOP2A gene amplification. Cen-
tromeres of chromosome 17 were detected by FITC green signals 
in single nucleus (b). Counterstained DAPI (a). Bar = 50 μm (a 
- c).
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an internal positive control of pre-treatment and hy-
bridization efficiency. 
Statistical Analysis
Descriptive data were defined as frequencies ±SD. 
The correlation between the BRCA1 protein expres-
sion and TOP2A protein and gene status defined by 
FISH methods was done using the Mann-Whitney 
test, χ2 test and Pearson’s correlation test. Calcula-
tions were performed using SPSS 11.0. A P value of 
<0.05 was considered to be statistically significant.
RESULTS
TOP2A gene and protein expression
Overexpression of the TOP2A protein was detected 
in 32 patients (32/53, 60.4%) (Fig. 1a, b). Signifi-
cant differences in TOP2A protein expression was 
detected between Luminal A and Luminal B breast 
cancer molecular subtypes (Table 2). Of the 53, 22 
(41.5%) patients showed TOP2A gene amplification 
Table 1. List of antibodies
Antibody Mo/PoAntigen unmasking technique Manufactured Code No. Dilution Detection system




Pressure cooker -2min 







Pressure cooker -2min 
0.01M citrate retrieval solution pH6.0 
Novocastra Lab., UK
NCL-L- PGR-312 1:100 LSAB+ /HRP




Water bath 40min, 
0.01M citrate retrieval solution pH6.0 
or DAKO cytomation target retrieval 










0.01M citrate retrieval solution pH6.0 
or DAKO cytomation target retrieval 
solution No. S1700 
Novocastra Lab., UK
NCL-TOPOIIA 1:100 LSAB+ /HRP





0.01M citrate retrieval  solution pH6.0 
or DAKO cytomation target retrieval  
solution  No. S1700 
Oncogene Research Products, 
Cat# OP92 1:100 LSAB+ /HRP
Fig. 3. The number of TOP2A+ and TOP2A-, BRCA1+ and 
BRCA1- breast cancer cells in four molecular breast cancer sub-
types. A – Luminal B subtype: TOP2A+ vs. TOP2A- (χ2=7.348, 
p=0.01); b - Luminal A subtype: BRCA1+ vs. BRCA1- (χ2=5, 
p=0.05); c - Luminal B subtype: BRCA1+ vs BRCA1- (χ2=7.348, 
p=0.05)).
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and 4 (7.4%) patients showed TOP2A gene deletion 
(Table 2). Amplification of the TOP2A gene (Fig. 
2) was detected in 6 (30%) patients Luminal A, 11 
(47.8%) patients Luminal B, 4 (66.7%) patients in 
HER-2 positive and 1 (25%) patients in triple-neg-
ative breast cancer subtypes. The amplification ra-
tios in these 22 tumors ranged from 2.2 to 8.2. No 
TOP2A gene amplification was found in 27 (50.9%) 
tumors (Table 2). Deletion of TOP2A was seen in 1 
(5%) out of 20 Luminal A tumors and in 3 (13%) out 
of 23 Luminal B tumors. Of 22 tumors with TOP2A 
amplification, 15 (68.2%) overexpressed TOP2A (4 
cases in Luminal A, 9 cases in Luminal B, 2 cases 
in the HER-2 positive subgroup) (Table 3). Only 13 
(48.1%) of 27 tumors without TOP2A amplification 
overexpressed TOP2A: 3 in Luminal A, 6 in Luminal 
B, 2 in triple-negative and 2 patients in HER-2 posi-
tive breast cancer subtypes (Table 3). The number of 
TOP2A positive breast cancer cases was statistically 
significantly higher in Luminal B breast cancer sub-
types in comparison to TOP2A negative cases (Fig. 
3). Correlation between the TOP2A gene and protein 
expression was positive but not statistically signifi-
cant (r=0.094, p=0.502) (Table 2). 
BRCA1 protein expression
The overexpression of BRCA1 protein was detected 
Table 2. Expression of TOP2A and BRCA1 in four molecular subtypes of breast cancer
Molecular subtypes of breast cancer





TOP2A IHC+ 8 (40 %)*,a 18(78.3%)*,b 2 (50 %)** 4 (66.7 %) 32 (60.4%)
TOP2A IHC- 12 (60%)a 5 (21.7%)b 2 (50 %)** 2 (33.3%) 21 (39.6%)
TOP2A FISH-gene amplification 6 (30 %) 11 (47.8 %) 1 (25%) 4 (66.7 %) 22 (41.5%)
TOP2A FISH-gene deletion 1 (5 %) 3 (13 %) 0 0 4 (7.6%)
TOP2A no amplification 13 (65%) 9 (39.2%) 3 (75%) 2 (33.3%) 27 (50.9%)
BRCA1 IHC+ 15 (75%)a 18 (78.3%)b    2 (50%)** 3 (50%) 38 (73.4%)
BRCA1 IHC-      5 (25%)a    5 (21.7%)b     2 (50%)** 3 (50%) 15 (26.6%)
*- TOP2A - Luminal A and Luminal B subtypes (U=142, p=0.01); **- triple-negative subtype: TOP2A and BRCA1 (r=1, 
p=0.01); a - Luminal A subtype: TOP2A and BRCA1 (r=0.471, p=0.05); b - Luminal B subtype: TOP2A and BRCA1 
(r=0.489, p=0.05). 
Table 3. Correlation between TOP2A gene amplification and deletion with TOP2A protein overexpression in four molecular subtypes 
of breast cancer
Molecular subtypes of breast cancer
Luminal A Luminal B Triple negative HER-2 positive
TOP2A+/TOP2A amplification 4 (20%) 9 (39.2%) 0 2 (33.3%)
TOP2A-/TOP2A amplification 2 (10%) 2 (8.7%) 1 (25%) 2 (33.3%)
TOP2A+/TOP2A deletion 1 (5%) 3 (13%) 0 0
TOP2A-/TOP2A deletion 0 0 0 0
TOP2A+/TOP2A no amplification 3 (15%) 6 (26.1%) 2 (50%) 2 (33.4%)
TOP2A-/TOP2A no amplification 10 (50%) 3 (13%) 1 (25%) 0
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in 38 patients (38/53, 71.7%): 15 cases in Luminal A, 
18 cases in Luminal B, 3 cases in HER-2 positive and 
2 cases in triple-negative molecular subtypes (Table 
2). 
In Luminal A (χ2=5, p=0.05) and B (χ2=7.348, 
p=0.05) breast cancer subtypes, statistically sig-
nificantly more BRCA1 protein positive cases were 
observed in comparison to BRCA1 negative breast 
cancer cases (Fig. 3). BRCA1 protein overexpression 
showed significant positive correlation with TOP2A 
protein expression in Luminal A (r=0.471, p=0.05), 
Luminal B (r=0.489, p=0.05) and triple-negative 
(r=1, p=0.01) breast cancer subtypes (Table 2). 
DISCUSSION
Most of the studies that have investigated genetic 
aberrations in breast cancer cells have focused on 
HER-2 gene amplification and its relationship with 
the TOP2A gene aberration (Arriola et al., 2008). Ac-
cording to our knowledge, little is known about the 
relationship of BRCA1 protein expression with the 
TOP2A gene and protein aberration in four molecu-
lar subtypes of breast cancer. 
The genes BRCA1 and TOP2A are located on 
chromosome 17 (Järvinen et al., 1999; Järvinen et al., 
2003; Rosen et al., 2005). Owing to TOP2A proximity 
to the BRCA1 gene on chromosome 17 we originally 
thought that gene and protein aberration are present 
in the same cancer cells. 
BRCA1 protein overexpression is linked to fa-
milial breast cancers in patients with a positive 
family history (Rosen et al., 2005). Overexpres-
sion of BRCA1 protein has been detected in 71.7% 
of patients, slightly higher than the overexpression 
of TOP2A protein, which was detected in 60.4% of 
breast cancer patients. A completely positive agree-
ment was established between the overexpression 
of BRCA1 and TOP2A proteins in Luminal B and 
triple-negative breast cancer subtypes. 
The results of previous studies have shown that 
BRCA1 protein overexpression is associated with the 
negative expression of estrogen and progesterone re-
ceptors, as well as with the positive overexpression of 
the HER-2 receptor (Rosen et al., 2005). Our results 
agree, in part, with this statement, bearing in mind 
that the overexpression of the BRCA1 protein was 
detected in 2/3 of patients with Luminal B subtypes 
of breast cancer where the steroid receptors were 
positive. 
In contrast to previous results (Miyoshi et al., 
2008), our results showed that TOP2A protein over-
expression is higher in tumors with ER (78.3%) and 
PR (78.3%) receptor positivity, and HER-2 positiv-
ity (78.3 %) in Luminal B subtype of breast cancer. 
The same relationship was detected for BRCA1 pro-
tein and those three receptors in Luminal B breast 
cancer subtype. The highest number of patients with 
positive expression of BRCA1 and TOP2A proteins 
was detected in the Luminal B breast cancer subtype. 
This finding is supported by the fact that all patients 
with Luminal B breast carcinoma displayed positive 
expression of the HER-2 receptor,  The frequency of 
TOP2A and BRCA1 protein expression was identi-
cal in the subtypes of Luminal B and triple-negative 
breast cancer. 
The TOP2A gene is amplified in a significant 
number of breast cancer cases and might be the tar-
get for TOP2A inhibitors during the therapy. We 
identified TOP2A gene deletion in 13% (3/23) of 
Luminal B breast cancer subtype. We also identified 
one tumor with TOP2A deletion in Luminal A breast 
cancer without HER-2 protein overexpression. Our 
data demonstrated that TOP2A overexpression rare-
ly occurs in the absence of gene amplification, and it 
is also in correlation with previous results (Miyoshi 
et al., 2008). 
Our study showed that more than 31.8% of 
TOP2A gene amplification cases showed an absence 
of protein overexpression. Negative immunohisto-
chemical results in tumors with TOP2A gene ampli-
fication could be the consequence of several factors 
(Olsen et al., 2004; Miyoshi et al., 2008). One of the 
factors could be a loss of antigenicity during tissue 
processing. Another reason for this discrepancy be-
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tween gene amplification and protein overexpression 
might be the fact that TOP2A is a cell cycle regulated 
protein. The level of TOP2A protein expression is 
linked to the rate of cell proliferation. Its protein lev-
els change during the cell cycle without contribution 
of gene amplification. According to this finding, it is 
suggested that factors, other than gene amplification, 
also participate in the regulation of TOP2A protein 
expression (Miyoshi et al., 2008). 
A recent study has shown the importance of 
TOP2A as a predictive factor for epirubicin-based 
therapy in breast cancer. Miyoshi et al. (2008) re-
ported that patients with TOP2A gene amplifica-
tion and BRCA1 negative protein expression show 
an enhanced recurrence-free survival when treated 
with specific CEF therapy. A similar finding has 
been reported by Tanner et al. (2006) who also re-
ported better survival for patients with TOP2A gene 
amplification. Several studies showed that both im-
munohistochemically determined TOP2A protein 
expression and TOP2A gene amplification have 
been associated with response to epirubicin-based 
therapy. Cardoso et al. (2004) analyzed the expres-
sion of both TOP2A proteins as determined by im-
munohistochemistry and TOP2A gene amplifica-
tion as determined by FISH, and compared their 
association with response to epirubicin therapy. The 
results of this study showed a stronger prognostic 
association between TOP2A protein expression and 
epirubicin therapy (Cardoso et al., 2004). Accord-
ing to the literature, the association between TOP2A 
overexpression and TOP2A gene amplification is not 
so strong since only 33% of breast tumors with gene 
amplification show TOP2A protein overexpression 
(Miyoshi et al., 2008). In contrast to this statement 
our results showed a higher level of correlation be-
tween TOP2A gene amplification and protein over-
expression, especially in the Luminal B molecular 
subgroup (9/11, 81.8 %). 
TOP2A expression is of considerable clinical 
significance. As far as we know, we were the first to 
investigate the correlation between BRCA1 protein 
and TOP2A protein expression in four molecular 
subtypes of breast cancer. In conclusion, we dem-
onstrated that TOP2A and BRCA1 positive pheno-
types are in significant correlation in Luminal B and 
triple-negative breast cancer subtypes. On the basis 
of this result we suggest that BRCA1 and TOP2A 
protein expression have similar patterns in these 
two molecular subgroups, and that patients from 
these groups could benefit from epirubicin-based 
therapy.
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